We surround our companies with the downstream capital partners, strategics, and commercial relationships that accelerate revenue and impact.

We back US-based teams leveraging proprietary data to build scalable products and services, and work closely with teams as trusted advisors.
Breakthroughs shouldn’t take a generation to reach the people who need them.
That timeline is already shrinking. AI, proprietary biological data and new computing tools are compressing decades of discovery into months, and the tools making it possible are being built today.
Models keep getting better, but they are only as good as the data they learn from. Tools that make biological data easier to interpret, and analysis more precise, are the enabling layer for every model improvement to come.
Phase Capital invests in technology-first, revenue-generating companies (pre-seed – Series A) at the intersection of AI, biology, and proprietary data. We focus on the adaptive data layer of biotech: platforms that continuously generate proprietary biological data, building the foundational infrastructure from which future therapies, diagnostics, industrial biology, and entirely new categories of innovation will emerge.
“Phase Capital has been our most helpful investor.”
We surround our companies with the downstream capital partners, strategics, and commercial relationships that accelerate revenue and impact.
We put our founders in the rooms and on the stages where the right partners find them.
We do both through our annual Frontiers Summit and focused gatherings throughout the year.
The Frontiers Summit is our seminal annual event, convening thought-leaders and stakeholders from every spoke of the innovation flywheel. The Summit creates support and partnership opportunities and strengthens the broader national techbio ecosystem. Every attendee is invited into the Frontiers Network, which keeps those connections going between events.

